PMID- 28618376
OWN - NLM
STAT- MEDLINE
DCOM- 20180129
LR  - 20221207
IS  - 1872-6844 (Electronic)
IS  - 0920-1211 (Linking)
VI  - 135
DP  - 2017 Sep
TI  - Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: A 
      meta-analysis.
PG  - 19-28
LID - S0920-1211(16)30311-4 [pii]
LID - 10.1016/j.eplepsyres.2017.05.015 [doi]
AB  - PURPOSE: From our current understanding, the association between the human 
      leukocyte antigen (HLA), HLA-B*1502, and carbamazepine(CBZ)-induced 
      Stevens-Jonson syndrome and toxic epidermal necrolysis (SJS/TEN) in the Asian 
      population is quite clear. However the relationship between other HLA-B alleles 
      and CBZ-induced severe cutaneous adverse drug reactions (SCADRs) remains unclear. 
      We aimed to identify other non-HLA-B*1502 alleles in patients with CBZ-induced 
      SCADRs through a meta-analysis. MATERIALS AND METHODS: A thorough literature 
      search was performed using Embase, PubMed, Web of Knowledge and Cochrane 
      databases. A meta-analysis was performed from their inceptions to May 31, 2016. 
      Studies investigating the association of HLA-B alleles and CBZ-induced SJS/TEN 
      were retrieved. Two reviewers independently extracted the data. Overall odds 
      ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated 
      using the RevMan 5.3 software. RESULTS: A total of 11 studies met the inclusion 
      criteria, totaling 343 CBZ-induced SJS/TEN cases, 838 CBZ tolerant controls, and 
      978 population controls. We observed HLA-B*1511 as a risk marker, and HLA-B*4001 
      and HLA-B*4601 as protective markers for the development of SJS/TEN in patients 
      taking CBZ. SJS/TEN cases were found to be significantly associated with 
      HLA-B*1511 in both the tolerant group (OR=17.43;95%CI=3.12-97.41;P=0.001) and the 
      population-control group (OR=11.11; 95%CI=2.62-47.09; P=0.001). The sensitivity 
      analysis found that HLA-B*5801 was a protective marker in the Southeast Asian 
      population (OR=0.23; 95%CI=0.09-0.58; P=0.002). CONCLUSION: Our study 
      demonstrated that in the Asian population, HLA-B*4001, HLA-B*4601, HLA-B*5801 
      were strong protective factors in the development of CBZ-induced SJS/TEN whereas 
      HLA-B*1511 was a risk factor. While more studies may be needed in order to 
      confirm these findings, consideration should be taken into testing Asian patients 
      for at-risk alleles prior to CBZ therapy initiation.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Wang, Qianyu
AU  - Wang Q
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Sun, Shusen
AU  - Sun S
AD  - College of Pharmacy, Western New England University, Springfield, MA, United 
      States.
FAU - Xie, Meng
AU  - Xie M
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zhao, Kun
AU  - Zhao K
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China; College of Pharmacy, Western New England University, Springfield, 
      MA, United States.
FAU - Li, Xingang
AU  - Li X
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China. Electronic address: lxg198320022003@163.com.
FAU - Zhao, Zhigang
AU  - Zhao Z
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China. Electronic address: 1022zzg@sina.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20170603
PL  - Netherlands
TA  - Epilepsy Res
JT  - Epilepsy research
JID - 8703089
RN  - 0 (HLA-B Antigens)
RN  - 33CM23913M (Carbamazepine)
SB  - IM
MH  - Asian People/genetics
MH  - Carbamazepine/*adverse effects
MH  - Genetic Predisposition to Disease
MH  - HLA-B Antigens/*genetics
MH  - Humans
MH  - Stevens-Johnson Syndrome/*genetics
OTO - NOTNLM
OT  - Carbamazepine
OT  - Human leukocyte antigen
OT  - Meta-analysis
OT  - Stevens-Johnson syndrome
OT  - Toxic epidermal necrolysis
EDAT- 2017/06/16 06:00
MHDA- 2018/01/30 06:00
CRDT- 2017/06/16 06:00
PHST- 2016/12/23 00:00 [received]
PHST- 2017/05/15 00:00 [revised]
PHST- 2017/05/27 00:00 [accepted]
PHST- 2017/06/16 06:00 [pubmed]
PHST- 2018/01/30 06:00 [medline]
PHST- 2017/06/16 06:00 [entrez]
AID - S0920-1211(16)30311-4 [pii]
AID - 10.1016/j.eplepsyres.2017.05.015 [doi]
PST - ppublish
SO  - Epilepsy Res. 2017 Sep;135:19-28. doi: 10.1016/j.eplepsyres.2017.05.015. Epub 
      2017 Jun 3.